Aytu BioPharma Recaps Investor Day Held on January 20, 2026 Aytu BioPharma (Nasdaq:AYTU) held Investor Day on January 20, 2026 focused on EXXUA (gepirone) ER, the first FDA‑approved 5HT1a agonist for major depressive disorder (MDD) that launched commercially on December 15, 2025. Management reviewed pivotal Phase 3 results showing statistically significant HAM‑D17 improvement versus placebo (placebo‑subtracted differences of −2.47 and −2.45 at Week 8) and safety data from ~1,976 MDD patients. Company highlighted market opportunity (US MDD market > $22B), full national distribution, early prescription uptake, expected EXXUA gross margin of 66–68%, and key commercialization economics including a 28% base royalty and upfront payments tied to Fabre‑Kramer agreement.

#AYTU Aytu BioPharma Recaps Investor Day Held on January 20, 2026

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

#AYTU Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM) Aytu BioPharma (Nasdaq: AYTU) announced that the U.S. method‑of‑use patent (U.S. Patent No. 7,538,116) for EXXUA (gepirone) extended‑release tablets was extended under 35 U.S.C. 156 through September 2, 2030. The extension supplements the NCE exclusivity previously granted by the FDA for gepirone, described as the first‑in‑class selective serotonin 5HT1a receptor agonist approved for treatment of major depressive disorder (MDD) in adults.Management said EXXUA is on track for commercial launch in 2025 and that the company is discussing additional intellectual property and life‑cycle management options with its partner that may extend exclusivity beyond 2030. The release also cites an estimated 21 million Americans affected by MDD as the target patient population.

#AYTU Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM) Aytu BioPharma (NASDAQ:AYTU) reported its fiscal 2025 results with net revenue of $66.4 million, a 2% increase from fiscal 2024. The company posted a net loss of $13.6 million and adjusted EBITDA of $9.2 million, with a strong cash position of $31.0 million as of June 30, 2025.The company's ADHD Portfolio generated $57.6 million in revenue, while the Pediatric Portfolio contributed $8.8 million. A significant highlight is Aytu's exclusive agreement to commercialize EXXUA, a novel first-in-class treatment for major depressive disorder (MDD), with launch planned for Q4 2025 targeting the $22 billion U.S. MDD market.

#AYTU Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

News; ( NASDAQ: #AYTU ) Expected earnings - Aytu BioPharma, Inc.

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Tue Jul 8th - #ULCC #RAPT #PRTA #MRKR #LTBR #KIRK #IKNA #GLRE #FDMT #EVAX #ONTH #STAA #TVNA #BLFS #BRCP #AYTU #ZEPP #VLRS #SEMR #OBK #LUXE #HBI #CHCG #REPL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) Aytu BioPharma has expanded and extended its lending agreement with Eclipse Business Capital, strengthening its financial position ahead of EXXUA's commercial launch. The term loan maturity has been extended to June 2029, with the principal balance increased to $13.0 million from $11.1 million. The revolving credit facility has been expanded by $1.5 million. This follows Aytu's recent exclusive agreement to commercialize EXXUA, a first-in-class antidepressant for major depressive disorder, in the U.S. market worth over $22 billion. EXXUA has shown promising results in clinical trials with over 5,000 patients, demonstrating significant improvement in depression symptoms with sexual side effects comparable to placebo. The company recently closed a $16.6 million public offering and plans to launch EXXUA in Q4 2025.

#AYTU Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

Just In: ( NASDAQ: #AYTU ) Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

Aytu is in the Headlines with Exclusive EXXUA Deal and $14.4M Public Offering to Drive Growth in Depression Market Aytu BioPharma (NASDAQ: AYTU) made headlines today with two major announcements: the exclusive U.S. commercialization rights to EXXUA™ (gepirone), a first-in-

#AYTU is making waves with an exclusive U.S. licensing deal for Exxua® and a $14.4M public offering. The company is strategically advancing its position in the growing depression treatment market.
#AytuBioPharma
prismmarketview.com/aytu-is-in-t...

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results Aytu BioPharma (NASDAQ:AYTU) reported strong financial results for Q3 FY2025. The company achieved total net revenue of $18.5 million, up 32% year-over-year, driven by growth in both ADHD and Pediatric portfolios. The ADHD Portfolio revenue increased 25% to $15.4 million, while the Pediatric Portfolio saw a 77% increase to $3.1 million. The company reported net income of $4.0 million ($0.65 basic and $0.21 diluted EPS), compared to a net loss in Q3 FY2024. Adjusted EBITDA improved to $3.9 million from $0.9 million year-over-year. Cash position stood at $18.2 million, with the company reducing long-term debt by $2.5 million during the quarter. Gross profit was $12.8 million (69% margin), slightly down from 74% in the previous year due to temporary manufacturing transition costs.

#AYTU Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Aytu BioPharma (AYTU) reported fiscal Q2 2025 results with net income of $0.8 million and Adjusted EBITDA of $1.3 million. The company's Pediatric Portfolio showed strong performance with an 86% sequential increase in net revenue to $2.4 million, while the ADHD Portfolio revenue increased 16% sequentially to $13.8 million (adjusted for one-time effects).Total net revenue was $16.2 million, with both portfolios showing the first quarterly sequential prescription growth since late-2022. The company maintained a strong cash position of $20.4 million as of December 31, 2024. Gross profit was $10.8 million (66% of net revenue), down from 78% in the previous year due to temporary manufacturing transition costs.The company completed its strategic restructuring, including the divestiture of its Consumer Health business and closure of its Texas manufacturing facility, expecting at least $2.0 million in additional annual cost savings.

#AYTU Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

JUST IN: ( NASDAQ: #AYTU ) Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

#StockMarket #News

#AYTU Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

#AYTU Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

www.stocktitan.net/news/AYTU/aytu-bio-pharm...

BREAKING NEWS: ( NASDAQ: #AYTU ) Expected US Company Earnings on Thursday, September 26th, 2024

#StockMarket #News